Telix Pharmaceuticals Ltd (ASX: TLX) is a biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation. The company is developing a portfolio of oncology products that address medical needs for renal, prostate and brain cancer.
Today, the company has announced the establishment of Telix Pharmaceuticals (Japan) Ltd and appointed the first two members of the Japanese team.
The aim of the Japanese company is to support Japanese clinical and radiopharmaceutical manufacturing activities and establish a commercial footprint in Japan.
Telix Co-Founder and CEO Dr. Christian Behrenbruch stated "Japan is one of the most prospective markets for Telix's products and our activities in Japan covers are range of manufacturing and collaboration activities with leading Japanese sites and biopharmaceutical companies."
"The Japanese radiopharmaceutical landscape is evolving rapidly and we are pleased to have been able to hire two extremely high-caliber executives to lead our development and commercial activity."
